Fig. 6: High METTL3 expression is involved in the development of resistance to enzalutamide.

A, B Cell viability assay following treatment for 48 h with indicated concentrations of enzalutamide in C4-2/C4-2R and LNCap/LNCap^R cell lines. C Western blotting showed the protein alteration of METTL3 in long-term enzalutamide treated in LNCap and C4-2 cell lines. D The total m⁶A levels of C4-2 and C4-2^R cell lines were detected by dot blotting assay. E–G qPCR and Western blotting showed the mRNA and protein levels of METTL3, HRAS, MEK2 and phosphorylation of ERK between C4-2^R sh-con/LNCap^R sh-con and C4-2^R sh-METTL3/LNCap^R sh-METTL3 cell lines. H An MTT assay was used to detect the changes of cell viability before and after METTL3 knockdown in the C4-2^R and LNCap^R cell lines. Cells were cultured with enzaluamide (20 nm). A P value of < 0.05 was considered significant. ***represents P < 0.001. I The cell proliferation of C4-2^R and LNCap^R cell lines before and after METTL3 knockdown was detected by plate cloning assay. J Transwell assays were used to detect the migration and invasion abilities of C4-2^R and LNCap^R cells before and after METTL3 knockdown.